| Our Company

ExThera Medical develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter, and OncoBind™ Blood Filter for removing a broad range of harmful substances from the bloodstream of patients. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections, and the potential to treat stage 4 metastatic cancer patients. With a growing body of outcome and health economic evidence from independent clinical studies, participation in the DARPA dialysis-like therapeutics program, from successful clinical use in the U.S. and EU for the treatment of bloodstream infections, and with positive in vitro test results demonstrating removal of circulating tumor cells, the company is well-positioned to serve healthcare professionals and patients alike.

ExThera Medical was formed in 2008 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm with a focus on therapeutic applications to address antimicrobial resistance (AMR). From this collaboration, the application of novel pathogen and circulating tumor cell adsorption intellectual property was developed to what is now branded as the Seraph® 100 and OncoBind™ blood filters.

ExThera Medical is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual’s race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.                                                                                                                                                                                                                                                                                             07Mar24 -01